NO20030111L - Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse - Google Patents

Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse

Info

Publication number
NO20030111L
NO20030111L NO20030111A NO20030111A NO20030111L NO 20030111 L NO20030111 L NO 20030111L NO 20030111 A NO20030111 A NO 20030111A NO 20030111 A NO20030111 A NO 20030111A NO 20030111 L NO20030111 L NO 20030111L
Authority
NO
Norway
Prior art keywords
terminus
chemokine receptor
treatment
terminal
analogs
Prior art date
Application number
NO20030111A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030111D0 (no
Inventor
Robin E Offord
Olivier Hartley
Hubert Gaertner
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Publication of NO20030111D0 publication Critical patent/NO20030111D0/no
Publication of NO20030111L publication Critical patent/NO20030111L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20030111A 2000-07-12 2003-01-09 Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse NO20030111L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21768300P 2000-07-12 2000-07-12
PCT/US2001/021934 WO2002004499A1 (en) 2000-07-12 2001-07-12 Chemokine receptor modulators, production and use

Publications (2)

Publication Number Publication Date
NO20030111D0 NO20030111D0 (no) 2003-01-09
NO20030111L true NO20030111L (no) 2003-03-12

Family

ID=22812056

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20030110A NO20030110L (no) 2000-07-12 2003-01-09 Polymer-modifiserte bioaktive syntetiske kjemokiner, fremgangsmåter for deres fremstilling og anvendelse
NO20030111A NO20030111L (no) 2000-07-12 2003-01-09 Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20030110A NO20030110L (no) 2000-07-12 2003-01-09 Polymer-modifiserte bioaktive syntetiske kjemokiner, fremgangsmåter for deres fremstilling og anvendelse

Country Status (14)

Country Link
US (1) US20050089970A1 (ja)
EP (2) EP1307216A4 (ja)
JP (3) JP2004502783A (ja)
KR (2) KR20030036591A (ja)
CN (2) CN1460023A (ja)
AU (2) AU2002218769A1 (ja)
BR (2) BR0112429A (ja)
CA (2) CA2412150A1 (ja)
IL (2) IL153789A0 (ja)
MX (2) MXPA03000310A (ja)
NO (2) NO20030110L (ja)
RU (1) RU2003104024A (ja)
WO (2) WO2002004015A1 (ja)
ZA (2) ZA200300313B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482425B2 (en) 1999-08-26 2009-01-27 Amylin Pharmaceuticals, Inc. Compositions for lipid matrix-assisted chemical ligation
JP2004508338A (ja) 2000-09-08 2004-03-18 グリフォン　セラピューティクス，インコーポレーテッド ポリマー修飾合成タンパク質
US7541435B2 (en) * 2002-06-12 2009-06-02 Merck Serono Sa Antagonists of cxcr3-binding cxc chemokines
WO2004017999A1 (en) * 2002-08-16 2004-03-04 University Of Bern Non-glycosylated polyacrylamide conjugates and their use for cytoprotection
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
JP2007501812A (ja) * 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
JP4895826B2 (ja) 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成蛋白−２の正のモジュレーター
EP1732942A4 (en) * 2004-03-30 2008-12-03 Amylin Pharmaceuticals Inc SYNTHETIC CHEMOKINES, MANUFACTURING METHODS AND APPLICATIONS
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
CN100467487C (zh) * 2004-12-14 2009-03-11 北京大学 具有多种功能的多肽
WO2006069449A1 (en) * 2004-12-29 2006-07-06 The University Of British Columbia Chemokine receptor-independent immunomodulatory and anti-proliferative activity
EP1951869A1 (en) * 2005-11-11 2008-08-06 Proteogen Bio S.R.L. Method of converting water-soluble active proteins into hydrophobic active proteins, the use of the same for the preparation of monomolecular layers of oriented active proteins, and devices comprising the same
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
US10741034B2 (en) * 2006-05-19 2020-08-11 Apdn (B.V.I.) Inc. Security system and method of marking an inventory item and/or person in the vicinity
JP2009541358A (ja) 2006-06-22 2009-11-26 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成を強化するためにｂｍｐ−２増幅因子／共活性化因子を送達するための組成物および方法
WO2008080116A2 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California New fusion molecule based on novel taa variant
TWI405779B (zh) * 2007-08-01 2013-08-21 私立中原大學 兩性高分子及其形成方法與應用
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
WO2011097567A1 (en) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
EP2867251B1 (en) * 2012-06-29 2019-08-21 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
US10995371B2 (en) 2016-10-13 2021-05-04 Apdn (B.V.I.) Inc. Composition and method of DNA marking elastomeric material
US10920274B2 (en) 2017-02-21 2021-02-16 Apdn (B.V.I.) Inc. Nucleic acid coated submicron particles for authentication
CN110892990B (zh) * 2019-10-11 2023-03-31 内蒙古伊利实业集团股份有限公司 益生菌益生元食用组合物及其应用
CN112129946A (zh) * 2020-08-16 2020-12-25 陆修委 无糖链型惰性蛋白封闭剂的制备方法及应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3815826A1 (de) * 1988-05-09 1989-11-23 Henkel Kgaa Verfahren zur herstellung von vicinal diacyloxysubstituierten verbindungen
US5470829A (en) * 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JPH04503607A (ja) * 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5275838A (en) * 1990-02-28 1994-01-04 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
WO1992004942A1 (en) * 1990-09-19 1992-04-02 Atlantic Richfield Company High-stability foams for long-term suppression of hydrocarbon vapors
FR2672053B1 (fr) * 1991-01-30 1993-04-23 Atochem Polyether bloc amides, leur procede de synthese.
FR2673946B1 (fr) * 1991-03-15 1993-05-28 Atochem Polyether bloc amides, leur procede de synthese.
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
DE69310148T2 (de) * 1992-02-13 1997-07-31 Carlsberg As Polyethylenglykol oder polypropylenglykol enthaltend polymer
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5589356A (en) * 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
WO1995033490A1 (en) * 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5646285A (en) * 1995-06-07 1997-07-08 Zymogenetics, Inc. Combinatorial non-peptide libraries
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CA2226299A1 (en) * 1995-08-11 1997-02-27 Dendritech, Inc. Hyper comb-branched polymer conjugates
ATE523211T1 (de) * 1995-12-18 2011-09-15 Angiodevice Internat Gmbh Vernetzte polymerzusammensetzungen und verfahren zu deren verwendung
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
BR9711009A (pt) * 1996-08-02 1999-08-17 Ortho Mcneil Pharm Inc Polipeptidio tendo um polimero solÚvel em gua n-terminal covalentemente ligado
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6214540B1 (en) * 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
US6844161B2 (en) * 1997-09-04 2005-01-18 Gryphon Therapeutics, Inc. Modular protein libraries and methods of preparation
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US6111107A (en) * 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
JP4454152B2 (ja) * 1998-07-22 2010-04-21 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物
JP2004508338A (ja) * 2000-09-08 2004-03-18 グリフォン　セラピューティクス，インコーポレーテッド ポリマー修飾合成タンパク質

Also Published As

Publication number Publication date
AU2001273387A1 (en) 2002-01-21
KR20030036591A (ko) 2003-05-09
CA2412162A1 (en) 2002-01-17
CA2412150A1 (en) 2002-01-17
EP1307216A4 (en) 2005-01-12
KR20030032977A (ko) 2003-04-26
RU2003104024A (ru) 2004-06-27
NO20030111D0 (no) 2003-01-09
AU2002218769A1 (en) 2002-01-21
ZA200300312B (en) 2004-02-04
CN1441808A (zh) 2003-09-10
WO2002004499A1 (en) 2002-01-17
EP1299415A1 (en) 2003-04-09
JP2007302667A (ja) 2007-11-22
EP1307216A1 (en) 2003-05-07
BR0112428A (pt) 2003-11-25
US20050089970A1 (en) 2005-04-28
BR0112429A (pt) 2003-12-30
CN1460023A (zh) 2003-12-03
JP2004502783A (ja) 2004-01-29
NO20030110L (no) 2003-03-12
NO20030110D0 (no) 2003-01-09
EP1299415A4 (en) 2005-01-19
MXPA03000310A (es) 2004-12-13
JP2004517040A (ja) 2004-06-10
WO2002004015A9 (en) 2003-08-07
MXPA03000311A (es) 2004-12-13
ZA200300313B (en) 2004-02-04
IL153785A0 (en) 2003-07-31
IL153789A0 (en) 2003-07-31
WO2002004015A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
NO20030111L (no) Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse
JP4478714B2 (ja) イガイ接着蛋白質
Graziano et al. Guanine nucleotide-binding regulatory proteins; mediators of transmembrane signaling
CR8789A (es) Anticuerpos que se unen a il-13
NO953643D0 (no) Nytt middel til kontroll av celleaktivitet
DK0730587T3 (da) 3-phenyl-2-isoxazoliner som anti-inflammatoriske midler
NO20073958L (no) Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer
AU2002305323A1 (en) Fused heterocyclic compounds
NO20052728L (no) Substituerte tricykliske gamma-karboliner som serotonin reseptor agonister og antagonister
BR0213596A (pt) Sistema e metodo para transmitir sinais de midia
BR0116379A (pt) Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila
DK0730588T3 (da) Isoxazolinforbindelser som antiinflammatoriske midler
Ryu et al. Protein‐stabilizing and cell‐penetrating properties of α‐helix domain of 30Kc19 protein
Oliver‐Kozup et al. The group A streptococcal collagen‐like protein‐1, Scl1, mediates biofilm formation by targeting the extra domain A‐containing variant of cellular fibronectin expressed in wounded tissue
GB2427550A (en) Y2/Y4 selective receptor agonists for therapeutic interventions
NO20075781L (no) Diarylsulfone-sulfonamider og deres anvendelse
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
BR0308185A (pt) Processo para a produção de fluidos de hidrocarboneto
NO20026242L (no) Syntesemetoder for aplidin og nye antitumorale derivater, metoder for deresfremstilling og anvendelse av disse
NO20071919L (no) 4-((fenoksyalkyl)tio)-fenoksyeddiksyre og analoger
NO20072005L (no) Nye heterocykliske amider
NO20073239L (no) TNF-antagonister
PE20200150A1 (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
NO20054225L (no) Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister
ATE308335T1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application